Media Relations: Senesco Technologies, Inc. FD FD Bruce Galton Brian Ritchie Irma Gomez-Dib Chief Executive Officer brian.ritchie@fd.com irma.gomez-dib@fd.com bgalton@senesco.

TECHNOLOGIES INC. ANNOUNCES THE APPOINTMENT OF DR. HARLAN W. WAKSAL, M.D. AS

CHAIRMAN OF THE BOARD OF DIRECTORS AND THE ADDITION OF MR. WARREN J. ISABELLE,

CFA TO ITS BOARD OF DIRECTORS

BRUNSWICK, N.J. (June 9, 2009) - Senesco Technologies, Inc.

("Senesco" or the "Company") (NYSE Amex: SNT) today announced the appointment,

effective June 8, 2009, of its current Board member, Dr. Harlan Waksal, M.D., to

serve as Chairman of the Board, succeeding Mr. Rudolf Stalder, who has been the

Company's Chairman since January 2000. Mr. Stalder will

continue serving on the Board and also serve as a member of a newly formed

Executive Committee that includes Dr. Harlan Waksal, Mr. Christopher Forbes and

Waksal joined the Board of Senesco in October 2008. Dr. Waksal is

President and sole Proprietor of Waksal Consulting L.L.C. in Montclair,

NJ. From 1984 through July 2003 he was with ImClone Systems Inc., New

York, NY, serving most recently as President, Chief Executive Officer and Chief

Waksal is a member of the Board of Trustees of Oberlin College Ohio, a member of

the Board of Trustees and chair of the New Jersey Region of the American

Committee for the Weizmann Institute of Science in New York, and a member of the

Board of Trustees of the Montclair Art Museum.

is also pleased to announce, effective June 8, 2009, the appointment of Mr.

Warren J. Isabelle, CFA to the Board. Mr. Isabelle is a founder and

principal of Ironwood Investment Management L.L.C., located in Boston,

MA. From 1983-1997 Mr. Isabelle was with Pioneer Management

Corporation where he served most recently as Director of Research and Head of

U.S. Equities. Mr. Isabelle also serves as a member of the Public

Board and the Investment Committee of the University of Massachusetts

Stalder commented, "With Senesco's groundbreaking technologies, its research

focus on human health and its plans to move diligently into clinical trials with

a Multiple Myeloma cancer project, the recent addition of Dr. Waksal to

Senesco's Board gave us a unique opportunity to ask him to take on these new

responsibilities as Chairman of the Board. His experience in this

area will best serve our efforts moving forward. We are very pleased

about his acceptance of this significant role."

Waksal commented about his new responsibilities, "I am excited to take on this

new role in a company that is applying cutting edge science to areas of unmet

medical need. The evolving and significant scientific work and the near term

possibility of entering human studies make this a particularly promising time

for Senesco. I look forward to helping bring this work to fruition through my

interaction with management in my new role."

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger

or delay cell death in mammals (apoptosis) to determine if the technology is

applicable in human medicine. Accelerating apoptosis may have applications

to development of cancer treatments. Delaying apoptosis may have

applications to certain diseases inflammatory and ischemic diseases.

Senesco takes its name from the scientific term for the aging of plant cells:

senescence. Delaying cell breakdown in plants extends freshness after

harvesting, while increasing crop yields, plant size and resistance to

environmental stress. The Company believes that its technology can be used

to develop superior strains of crops without any modification other than

delaying natural plant senescence. Senesco has partnered with leading-edge

companies engaged in agricultural biotechnology and earns research and

development fees for applying its gene-regulating platform technology to enhance

its partners' products.

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of

1995. Actual results could differ materially from such statements

expressed or implied herein as a result of a variety of factors, including, but

not limited to: the ability of the Company to consummate a financing; the

development of the Company's gene technology; the approval of the Company's

patent applications; the successful implementation of the Company's research and

development programs and joint ventures; the success of the Company's license

agreements; the acceptance by the market of the Company's products; success of

the Company's preliminary studies and preclinical research; competition and the

timing of projects and trends in future operating performance, the Company's

ability to meet its funding milestones under its financing transaction, the

Company's ability to continue to comply with the continued listing standards of

the AMEX, as well as other factors expressed from time to time in the Company's

periodic filings with the Securities and Exchange Commission (the

"SEC"). As a result, this press release should be read in conjunction

with the Company's periodic filings with the SEC. The forward-looking

statements contained herein are made only as of the date of this press release,

and the Company undertakes no obligation to publicly update such forward-looking

statements to reflect subsequent events or circumstances.